AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06417762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science communication curriculum Cohort 3
Description: Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy
Study NCT05249387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 and BAM8-22 application
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT05249387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 and BAM8-22 application after 5 minutes.
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT05249387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 application.
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
Study NCT05249387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle and BAM8-22 application.
Description: Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT04684667 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol Therapy for Infantile Hemangioma
Description: If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
Study NCT06786338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for subcutaneous (SC) injection
Study NCT06787638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full dose of Neostigmine
Description: • Group A: received 10ml (a full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively.
Study NCT06787638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: half dose of Neostigmine
Description: • Group B: received 10ml (a half dose of Neostigmine (0.04 mg/kg) plus Atropine (20 mic/kg+8ml normal saline).~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively.
Study NCT06785376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIY (Do It Yourself)
Description: DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
Study NCT06785376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUST
Description: TRUST is a single-session HIV self-testing training with facilitator
Study NCT06785376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.
Study NCT06785376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.
Study NCT06783582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based on Pender's health promotion model
Description: In addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
Study NCT06785220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL FACIAL FACILITATION
Description: A group will receive oral facial facilitation which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)
Study NCT06785220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL MOTOR THERAPY
Description: B group will receive oral motor therapy which included exercise for given,~1. A volcano bubbles~2. Party blower target~3. Bubble blowing~4. Curly straws
Study NCT06785220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL FACIAL FACILITATION WITH ORAL MOROR THERAY
Description: C group will receive oral facial facilitation and oral motor therapy which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)~5. A volcano bubbles~6. Party blower target~7. Bubble blowing~8. Curly straws
Study NCT06007924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
Study NCT06007924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib 200 mg twice daily 3 weeks on/1 week off
Study NCT06783179 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06784206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy
Description: Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death
Study NCT06786000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with mCIMT
Description: 20 minutes of anodal tDCS followed by 1 hour of the mCIMT program. The anodal electrode will be placed over the ipsilesional M1 (primary motor cortex, C3 or C4 according to EEG 10/20 system), and the cathodal electrode over the contralateral supraorbital area (Fp1 or Fp2) ). Leading to subthreshold depolarization to promote cortical excitation. And twelve different oriented tasks will be used during the 1-hour training period.
Study NCT06786000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with mCIMT
Description: 20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the contralesional M1, and the anodal electrode over the contralateral supraorbital area (Fp1 or Fp2). leading to subthreshold polarization to promote cortical inhibition. And twelve different oriented tasks will be used during the 1-hour training period.
Study NCT06786000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihemispheric tDCS combined with mCIMT
Description: 20 minutes of Bihemispheric tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the primary motor cortex (M1) of the contralesional hemisphere and the anodal electrode will be placed above the ipsilateral M1 position (C3 or C4 positions, according to the 10/20 EEG system). And twelve different oriented tasks will be used during the 1-hour training period.
Study NCT06786000 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS combined with mCIMT
Description: 20 minutes of sham tDCS followed by 1 hour of the mCIMT program. the same stimulation place and parameters will be used as in the anodal group. However, after 30 seconds of stimulation, the stimulator will switch off. This provides the participants with the experience of the initial itchy sensation that occurs during tDCS, which is required for efficient masking. And twelve different oriented tasks will be used during the 1-hour training period.
Study NCT06783452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Clinical Pilates Session:~Each clinical Pilates movement will have three difficulty levels: beginner, intermediate, and advanced. The progression criteria for increasing difficulty will be determined by the prevention of compensatory movements, the ability to activate target muscles, achieving more controlled movements during exercise, and maintaining a more stable posture. This program will include standard hip-focused as well as full-body clinical Pilates movements.
Study NCT06783452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Conventional Therapeutic Exercise Program:~The Conventional Therapeutic Physiotherapy Exercise Program will consist of strengthening exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors. Additionally, stretching exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors, will be included. Stretching exercises will be performed at a pain-free point where tension is felt, holding for 10-30 seconds to achieve a total duration of 60 seconds per muscle group. These exercises will represent standard hip-targeted exercises.~During the exercises, patients will be asked to rate their perceived exertion using the BORG scale (0-10). When the difficulty level reaches 5-6 points, progression will first be achieved by increasing the number of sets, followed by the use of resistance bands.
Study NCT06307405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: next generation sequencing
Description: All the enrolled patients had undergone fiberbronchoscopy and sputum had been retained. The collected alveolar lavage fluid and sputum were examined for mNGS and routine etiology, respectively
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-503 20mg
Description: BEBT-503 capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-503 40mg
Description: BEBT-503 capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-503 80mg
Description: BEBT-503 capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-503 120mg
Description: BEBT-503 capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-503 180mg
Description: BEBT-503 capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 20mg
Description: placebo capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 40mg
Description: placebo capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 80mg
Description: placebo capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 120mg
Description: placebo capsule
Study NCT05391880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 180mg
Description: placebo capsule
Study NCT06784232 — intervention group
Intervention type: PROCEDURE
Intervention: BARP
Description: deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
Study NCT06784232 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Periosteal Inhibition Technique
Description: Cortical lamina stabilized with human fibrin glue to preserve the buccal wall of the socket. The socket was then filled with collagen.
Study NCT06782815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
Study NCT06782815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: （1）Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; （2）Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.
Study NCT06784856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICC AR APP
Description: This study utilized Vuforia software and Unity 2022 LTS as the primary development platforms to create an AR-Enhanced and Game-Assisted Teaching curriculum. The designed PICC AR Exploration APP was developed for both iOS and Android platforms. The PICC-related content was based on the 8th Edition of the Infusion Therapy Standards of Practice published by the Infusion Nurses Society (INS) in 2021 and the 2022 Clinical Guidelines for Vascular Access Devices.~The required items for PICC care procedures were photographed and used to create 3D object elements and animations for developing AR scenarios and interactive gaming elements. The design and content of the PICC AR Exploration APP are described as follows:~Game Design Concept:~The PICC AR Exploration APP includes a learning unit system and a quiz unit system:~Learning Unit System Content:~Topic 1: Updates to guidelines and an introduction to clinical applications. Topic 2: PICC catheter care, dressing change steps, and techni
Study NCT06784856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Classroom Teaching and Case Sharing
Description: Introduction to Updated CVAD-PICC Guidelines and Clinical Applications~PICC Catheter Care Management of Common PICC-Related Complications Case Sharing on PICC Complication Management: Researchers
Study NCT06784388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation(DBS)
Description: During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
Study NCT06784388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
Study NCT06786728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: frusemide
Description: in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group
Study NCT06784661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Based Artificial Tear
Description: This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Study NCT06784661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Lipid Artificial Tear
Description: This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Study NCT06783803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Linkage Analysis
Description: WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies
Study NCT06783790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib, azacitidine, Venetoclax
Description: A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles
Study NCT06786143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Esmadem Education Model
Description: Application Application of the Research The implementation of the research was done in 3 steps.~Step 1: In the first stage of the research, after the risky pregnant women who come to the polyclinic are informed about the study, the participants who agree to participate and meet the criteria for inclusion in the research will be determined by randomization. After the pregnant women assigned to the training or control group sign the voluntary consent form and their consent is obtained, Personal InformationForm, Mishel Uncertainty in Illness Scale Depression-Anxiety-Stress Scale Depression-Anxiety-Stress Scale (DASÖ-21) scales will be applied. After the first interviews, the study group will be informed about the sessions and the training will start via zoom.~In educational sciences, since the number of groups is between 2-20 people in the acquisition of target behaviors at the conceptual level, two training groups will be created and 15 pregnant women will be in the first group, 15 preg
Study NCT05665569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flourish HEC, which contains BioNourish
Description: The Flourish HEC vaginal hygiene system comprises Balance intimate wash used daily, BioNourish vaginal moisturizing gel used daily, and BiopHresh homeopathic vaginal suppository containing probiotics, used once every 3 days. In addition, for all therapy requiring insertion in the clinic or at home, or for sex if desired, BioNude personal lubricant will be used. These four products are intended to allow the vaginal microbiome to self-correct by supporting the vaginal environment in terms of providing pH, osmolality, and lactic acid levels that match those in a healthy vagina.
Study NCT05665569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine pelvic physical therapy
Description: Routine pelvic physical therapy may include external and internal manual techniques, exercises, diaphragmatic breathing exercises, and other modalities.
Study NCT05665569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine pelvic physical therapy
Description: Routine pelvic physical therapy may include external and internal manual techniques, exercises, diaphragmatic breathing exercises, and other modalities.
Study NCT04912830 — intervention group
Intervention type: PROCEDURE
Intervention: Tension-free vaginal tape
Description: female incontinence surgery with polypropylene tape applied
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No pedaling, usual activity
Description: Maintain usual physical activity and diet for a period of 6 weeks.
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedaling at 60rpm
Description: 3 sessions per week of training for 6 weeks
Study NCT05153928 — intervention group
Intervention type: DRUG
Intervention: Norethisterone acetate
Description: Norethisterone acetate for 5 months
Study NCT05756712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Wonderlab Product
Description: Chew two tablets of Wonderlab Product for phase 1 (day 1)